Author: Ken Dropiewski

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES

Ghent, Belgium, 27 April 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces that in the context of the private placement of new shares and new subscription rights that was announced on 24 April 2023 and […]

GE HealthCare Expands Contrast Media Portfolio with Launch of MRI Agent Pixxoscan (gadobutrol)

The launch of Pixxoscan expands GE HealthCare’s portfolio of Magnetic Resonance Imaging (MRI) contrast agents, now offering two leading macrocyclic molecules to customers – Clariscan (gadoteric acid) and Pixxoscan (gadobutrol) Pixxoscan has the same active substance (gadobutrol) and the same qualitative and quantitative composition as the reference product, Gadovist® The […]

Northwell Marks Milestone Surgery: More Than 100 Heart Transplants

MANHASSET, N.Y.–(BUSINESS WIRE)–It was a day of celebration and reflection as cardiac doctors, surgeons, nurses and therapists gathered at Sandra Atlas Bass Heart Hospital (SABHH) at North Shore University Hospital (NSUH) on April 26 to celebrate a medial milestone for the health system and region – more than 100 heart transplants have been performed […]

US Heart & Vascular Expands to Kansas through Partnership with Heartland Cardiology

The Heartland Partnership Represents USHV’s First in Kansas. NASHVILLE, Tenn.–(BUSINESS WIRE)–US Heart & Vascular (“USHV”), a leading national provider of support services to cardiovascular physician practices, announced its partnership with Heartland Cardiology (“Heartland”), a Wichita-based cardiovascular physician practice focused on preventative care, diagnostic testing, curative procedures and electrophysiology services. With […]

Five-Year Results of the LEOPARD Trial published in the Journal of Vascular Surgery (JVS)

The LEOPARD (Looking at EVAR Outcomes by Primary Analysis of Randomized Data) trial is the first randomized controlled trial (RCT) comparing the outcomes of endovascular aneurysm repair (EVAR) using commercially available devices in a real-world population. IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to providing disruptive therapies for the interventional treatment […]

10-Year Data from the Medtronic ENGAGE OUS Registry is the First and Only Prospective, Industry Sponsored Global EVAR Registry to Demonstrate a Decade of Durable Outcomes in Real-World Setting

Presented at Charing Cross, 10-Year Clinical Data from Global ENGAGE OUS Registry Support Endurant Stent Graft System’s AAA Market-Leading Position Worldwide Medtronic today announced its EndurantTM abdominal aortic aneurysm (AAA) stent graft system continues to demonstrate long-term durability through proven outcomes in a real-world setting1. The 10-year Endurant Stent Graft Natural Selection […]

Avinger Receives 510(k) Clearance for Tigereye ST Image-Guided CTO Crossing System

REDWOOD CITY, CA / ACCESSWIRE / April 26, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced the company has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for […]